Showing 3681-3690 of 6035 results for "".
- CooperVision Presents 6-Year Data from MiSight 1 Day Studyhttps://modernod.com/news/coopervision-presents-6-year-data-from-misight-1-day-study/2478397/CooperVision is reporting the latest findings from its landmark MiSight 1 day clinical study, providing new insights about myopia management and the efficacy of the specially designed contact lens. Among many powerful outcomes are that nearly one in four children’s eyes originally fit with MiSigh
- Bausch + Lomb Announces New Scientific and Clinical Analyses to be Presented at American Academy of Optometry Annual Meetinghttps://modernod.com/news/bausch-lomb-announces-new-scientific-and-clinical-analyses-to-be-presented-at-american-academy-of-optometry-annual-meeting/2478386/Bausch + Lomb announced that three poster presentations will feature the company’s new silicone hydrogel (SiHy) daily disposable contact lens, Bausch + Lomb Infuse, during the virtual American Academy of Optometry (AAO) annual meeting (Oct. 7-22, 2020). “Over the past two decades, we have
- Outlook Therapeutics Provides Update on First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degenerationhttps://modernod.com/news/outlook-therapeutics-provides-update-on-first-approved-ophthalmic-formulation-of-bevacizumab-vikg-for-advanced-macular-degeneration/2478349/Outlook Therapeutics announced progress on its phase 3 clinical program for the first FDA-approved ophthalmic formulation of bevacizumab-vikg (Lytenava) for use in retinal indications (known as ONS-5010 for use in retinal indications). Outlook plans the commercial launch of ONS-5010 in 202
- Johnson & Johnson Vision to Introduce Tecnis Synergy Toric II IOL and Catalys System cOS 6.0 Software at the ESCRS 2020https://modernod.com/news/johnson-johnson-vision-to-introduce-tecnis-synergy-toric-ii-iol-and-catalys-system-cos-6-0-software-at-the-escrs-2020/2478331/Johnson & Johnson Vision announced the availability of two new developments in the treatment of cataracts for patients with astigmatism in Europe. Tecnis Synergy Toric II IOL with Tecnis Simplicity Delivery System is a continuous-range-of-vision lens engineered for rotational stability, which
- KKR to Acquire 1-800 Contacts from AEA Investorshttps://modernod.com/news/kkr-to-acquire-1-800-contacts-from-aea-investors/2478313/1-800 Contacts, the largest retailer of contact lenses in the US, announced a definitive agreement under which global investment firm KKR will acquire the company from AEA Investors. Financial terms of the transaction were not disclosed. “1-800 Contacts was founded 25 years ago to o
- Emmecell Announces FDA Acceptance of IND Application for EO2002 in Corneal Edemahttps://modernod.com/news/emmecell-announces-fda-acceptance-of-ind-application-for-eo2002-in-corneal-edema/2478310/Emmetrope Ophthalmics announced that the FDA has accepted the investigational new drug application (IND) for EO2002, its lead candidate for the treatment of corneal edema. The active IND enables Emmecell to initiate a phase 1 clinical trial designed to assess the tolerability, safety, and efficac
- Biomarker Indicating Neurodegeneration Identified in the Eyehttps://modernod.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye. Neurofilament light chain, a protein previously detected in cerebrospinal fluid and blood that is
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- Ophthalmic Societies Call on FDA to Keep Moxifloxacin on Bulk Substance Listhttps://modernod.com/news/ophthalmic-societies-call-on-fda-to-keep-moxifloxacin-on-bulk-substance-list/2478293/Several ophthalmic organizations have collectively sent a letter to the FDA requesting that the agency retain moxifloxacin as Category 1 for outsourcing facility use (503b), citing a demonstrated clinical need for the medication as a bulk substance. The request comes after the FDA, on July 31, ga